Drug Trial Radar · NCT04858256
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 29, 2023
Primary completion
Nov 2027
Study completion Nov 2028
Sponsor
- Lead sponsor
- University of Michigan Rogel Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Cancer Institute (NCI); Hoosier Cancer Research Network; CTI BioPharma
- First posted
- Apr 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Conditions
- T-Cell Neoplasm
- Lymphoproliferative Disorders
Interventions
PacritinibDrug
Pacritinib will be dosed at 200mg twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: Up to 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Not yet recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.